Business Context and Reporting Period
Company: Donaldson Company, Inc. (DCI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended July 31, 2025
Business Overview: A global leader in technology-led filtration products and solutions serving mobile, industrial, and life sciences markets. The company operates through three reportable segments: Mobile Solutions (62.1% of sales), Industrial Solutions (29.9%), and Life Sciences (8.0%).
Key Financial Metrics
| Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Net Sales | $3,690.9 | $3,586.3 | +2.9% |
| Gross Profit | $1,286.2 | $1,274.4 | +0.9% |
| Gross Margin | 34.8% | 35.5% | -0.7 pts |
| Operating Income | $495.4 | $544.1 | -9.0% |
| Net Earnings | $367.0 | $414.0 | -11.3% |
| Diluted EPS | $3.05 | $3.38 | -9.8% |
| Operating Cash Flow | $418.8 | $492.5 | -15.0% |
| Total Debt | $668.3 | $536.7 | +24.5% |
| Cash & Equivalents | $180.4 | $232.7 | -22.5% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased $104.6 million, driven by volume increases and pricing actions across all segments. Life Sciences saw the highest growth at 9.8%, while Mobile Solutions grew 1.8% despite declines in On-Road and Off-Road OEM sales.
- Impairment Charge: A non-recurring $62.0 million loss on impairment of intangible assets was recorded in Q3 2025. This included $46.6 million related to Univercells Technologies (bioprocessing) and $15.4 million related to Solaris (industrial bioreactors) due to lower-than-anticipated capital spending and market demand.
- Margin Compression: Gross margin decreased 0.7% due to higher manufacturing costs from footprint optimization and tariff-related inflation on LIFO inventory valuation.
- Debt Increase: Total debt rose by $131.6 million, primarily to finance a $71.2 million equity method investment in Medica S.p.A. and a new $200 million term loan facility.
- Restructuring: Restructuring expenses totaled $16.8 million in 2025 (vs. $6.4 million in 2024) related to global footprint and cost optimization.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects cash paid for capital expenditures in fiscal 2026 to be between $65 million and $85 million.
- Tariff Impact: The company expects annual costs related to recently implemented tariffs to be approximately $35 million (less than 1% of sales), largely offset by pricing increases. Risks remain regarding potential new tariffs from the U.S., China, and the EU.
- Strategic Priorities: Focus remains on extending market access in bioprocessing and alternative power, expanding connected service offerings in Industrial Solutions, and pursuing strategic acquisitions in high-margin areas.
- Key Risks:
- Supply Chain: Volatility in raw material costs (steel, petrochemicals) and potential disruptions.
- Geopolitical: Trade barriers, tariffs, and global economic conditions.
- Technology: Disruptive technologies (e.g., electrification) threatening demand for traditional filtration products.
- Cybersecurity: Vulnerability of IT systems and data privacy regulations.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the discounted cash flow analysis for the $62.0 million impairment charge in the Life Sciences segment.
- Tariff Mitigation: Assess the company's ability to pass on the estimated $35 million in tariff costs to customers without losing market share.
- Debt Covenants: Confirm continued compliance with financial covenants (interest coverage and leverage ratios) given the increased debt load.
- Medica Investment: Review the strategic rationale and expected returns on the $71.2 million equity investment in Medica S.p.A.
- Working Capital: Monitor the net cash cycle, which increased from 76 days to 85 days, indicating higher working capital requirements.